10-K: Baxter Reports Net Loss Amid Strategic Shifts and Product Recalls

Baxter International Inc. posted a net loss of $957 million in 2025, driven by significant impairment charges and product recalls, despite operational sales growth.

Summary

• Reported net sales of $11.24 billion in 2025, an increase of 6% on a reported basis and 3% on an operational sales basis compared to 2024.
• Incurred a net loss attributable to Baxter stockholders of $(957) million, or $(1.87) per diluted share, in 2025.
• Special items adversely impacted net income by $2.09 billion, or $4.08 per diluted share, in 2025.
• Generated $951 million in operating cash flows from continuing operations in 2025.
• Repaid $3.81 billion of legacy indebtedness in 2025, primarily using net after-tax proceeds from the Kidney Care business sale, and an additional $2.00 billion from a new notes offering.
• Completed the sale of its Kidney Care business on January 31, 2025, for $3.80 billion in cash, yielding approximately $3.3 billion in net after-tax proceeds.
• Completed the sale of its BioPharma Solutions (BPS) business on September 29, 2023, for $3.96 billion in cash, recognizing a $2.88 billion pre-tax gain ($2.59 billion net of tax).
• Initiated voluntary corrections and a temporary ship and installation hold for the Novum IQ Large Volume Pump (Novum LVP) in the U.S. and Canada in April and July 2025 due to under-infusion and set misloading issues, classified as Class I recalls by the FDA.
• Recorded approximately $105 million in charges in 2025 related to Novum LVP corrections, including sales reductions, returns, remediation costs, and inventory/contract asset write-downs.
• Incurred $133 million in pre-tax charges in 2025 due to damages and remediation costs from Hurricane Helene at its North Cove facility in September 2024.
• Recorded a $485 million goodwill impairment charge for the Front Line Care reporting unit within the Healthcare Systems & Technologies segment in the fourth quarter of 2025.
• Recognized a $290 million impairment charge for the Welch Allyn trade name within the Healthcare Systems & Technologies segment in the fourth quarter of 2025.
• Increased reserves for uncertain tax positions by approximately $280 million related to IRS transfer pricing matters for tax years 2019 through 2025.
• Recorded a valuation allowance against U.S. deferred tax assets due to a cumulative history of operating losses in the U.S.
• Reduced its quarterly dividend to $0.01 per share in November 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging period for Baxter, marked by significant net losses, substantial impairment charges, and critical product recalls impacting key segments. While strategic divestitures and debt reduction efforts are underway, the immediate financial performance and operational headwinds suggest a negative sentiment.

Positives

• Achieved overall net sales growth of 6% on a reported basis and 3% on an operational sales basis in 2025.
• Advanced Surgery segment net sales increased 9% (8% operational) in 2025, driven by increased sales volume in hemostats and sealants globally.
• Care and Connectivity Solutions net sales increased 5% (4% operational) in 2025, attributed to increased capital spending by U.S. customers and higher installations of care communications products.
• Drug Compounding net sales increased 10% (9% operational) in 2025, due to improved product mix and increased demand for international pharmacy compounding offerings.
• Operating cash flows from continuing operations improved to $951 million in 2025 from $819 million in 2024, reflecting improved profitability and working capital management.
• Successfully completed the sale of its Kidney Care business, generating $3.3 billion in net after-tax cash proceeds, which were primarily used for debt repayment.
• Successfully completed the sale of its BioPharma Solutions (BPS) business in 2023, generating $3.96 billion in cash proceeds and a significant pre-tax gain of $2.88 billion.
• Repaid a total of $5.81 billion in indebtedness in 2025, demonstrating commitment to deleveraging.
• The North Cove facility, impacted by Hurricane Helene in September 2024, was fully operational by the end of the first quarter of 2025.
• The FDA classified the June 2025 re-inspection of the Claris facilities in Ahmedabad, India, as Voluntary Action Indicated (VAI), indicating acceptable compliance and expected closure of the 2023 Warning Letter.

Negatives

• Reported a net loss of $(957) million in 2025, an increase from the $(638) million net loss in 2024.
• Net loss from continuing operations was $(900) million in 2025.
• Special items, totaling $2.09 billion, significantly impacted net income in 2025.
• Infusion Therapies & Technologies net sales were flat in 2025, primarily due to the Novum LVP hold and lower demand in IV Solutions following fluid conservation practices.
• Injectables and Anesthesia net sales decreased 2% in 2025, driven by pricing competition and lower demand in specialty injectables.
• Incurred $105 million in charges in 2025 related to voluntary corrections and Class I recalls for the Novum LVP, including a temporary ship and installation hold in the U.S. and Canada.
• Recorded a $485 million goodwill impairment charge for the Front Line Care reporting unit in Q4 2025 due to lower forecasted operating results and unfavorable valuation assumptions.
• Recognized a $290 million impairment charge for the Welch Allyn trade name in Q4 2025 due to lower forecasted revenues and margins.
• Gross margin ratio decreased significantly to 30.1% in 2025 from 37.5% in 2024, impacted by the Kidney Care MSA, product mix, manufacturing variances, tariffs, and inventory adjustments.
• Increased reserves for uncertain tax positions by approximately $280 million due to an ongoing IRS examination of transfer pricing matters.
• Recorded a valuation allowance against U.S. deferred tax assets due to a cumulative history of operating losses in the U.S.
• Reduced its quarterly dividend to $0.01 per share in November 2025, signaling financial constraints.
• Maintains significant indebtedness of $9.48 billion as of December 31, 2025, requiring substantial cash flow for debt service.
• Continues to face challenges with the integration of the Hillrom acquisition, which has taken longer and incurred more expenses than anticipated.
• Subject to class action and derivative lawsuits alleging false and misleading statements regarding the Novum LVP.

Risks

• Exposure to risks from strategic actions, including divestitures and acquisitions, potentially leading to a smaller, less diversified company and increased financial volatility.
• Failure to achieve anticipated benefits from significant transactions, such as the Kidney Care sale and Hillrom acquisition, including disputes with buyers, retained liabilities, adverse tax consequences, and significant ongoing expenses.
• Significant indebtedness ($9.48 billion as of December 31, 2025) requires substantial cash flow for debt service, constraining investments in R&D, capital expenditures, and other growth initiatives.
• Risk of not achieving the net leverage target of approximately 3.0x by the end of 2026, potentially leading to further credit rating downgrades and increased borrowing costs.
• Substantial competition in product markets, leading to declining demand, pricing pressures, and potential loss of market share if unable to innovate or respond to changing customer requirements.
• Inability to successfully introduce or monetize new or existing products or keep pace with changing consumer preferences and technology, potentially leading to product obsolescence and reduced sales/profitability.
• Failure to achieve financial goals, including net leverage targets and fully offsetting stranded costs from the Kidney Care sale.
• Disruptions in the global supply chain, including production delays, increased costs, and shortages of raw materials and components due to weather events, pandemics, inflation, and geopolitical events.
• Adverse effects of global economic conditions, including heightened inflation, capital markets volatility, interest rate and currency fluctuations, and economic slowdowns, impacting demand, cash flows, and customer payment ability.
• Inability to achieve expected operating efficiencies and sustain operating expense reductions from restructuring initiatives, potentially leading to business disruptions and adverse tax consequences.
• Continued consolidation in the healthcare industry or additional governmental controls over pricing and access, leading to increased demands for price concessions or market exclusion.
• Fluctuations in operating results and financial condition due to changes in expectations, strategy, macroeconomic conditions, or regulatory developments.
• Uncertainties from management transitions and difficulties in attracting and retaining key employees.
• Adverse effects of changes in foreign currency exchange rates and interest rates on results of operations, financial condition, cash flows, and liquidity.
• Future material impairments in goodwill, intangible assets, and other long-lived assets, as evidenced by the $485 million goodwill impairment and $290 million trade name impairment in 2025.
• Significant dependence on major contracts with Group Purchasing Organizations (GPOs), Integrated Delivery Networks (IDNs), and other distributors, with risks of not being awarded or maintaining agreements, increased costs, and pricing restrictions.
• Inability to obtain sufficient components or raw materials on a timely basis or for a cost-effective price, especially from single-source suppliers, leading to production delays, lost sales, and reputational harm.
• Manufacturing, sterilization, supply, or distribution difficulties due to complex processes, limited transport providers, facility damage (e.g., Hurricane Helene), or regulatory issues.
• Quality management or product quality issues, such as the Novum LVP recalls, leading to regulatory actions, product recalls, negative publicity, loss of customer confidence, and asset impairments.
• Breaches and breakdowns affecting information technology systems or protected information, including from obsolescence, cybersecurity breaches, and data leakage, with heightened risks from AI/ML integration and third-party service providers.
• Risks associated with incorporating AI, machine learning, and other emerging technologies into products and operations, including development/integration delays, regulatory scrutiny, and intellectual property challenges.
• Risks associated with doing business globally, including changes in exchange controls, taxation, tariffs, sanctions, political instability, and intellectual property protection.
• Potential labor disruptions from a unionized workforce.
• Adverse effects of climate change, including physical risks, compliance costs, and market shifts, on business, results of operations, financial condition, and cash flows.
• Failure to satisfy differing stakeholder expectations regarding sustainability and corporate responsibility matters, potentially leading to reputational damage or loss of business.
• Failure to comply with rapidly changing and divergent global laws and regulations (e.g., FDA, EU MDR, Anti-Kickback Statute, False Claims Act, FCPA, environmental laws, trade policies), leading to penalties, restrictions, or litigation.
• Reduced or modified reimbursement for products in the U.S. or foreign countries due to healthcare reform, cost containment measures, or changes to pricing/taxation policies.
• Increasing regulatory focus on privacy, AI, and cybersecurity laws, potentially exposing the company to increased liability.
• Ongoing lawsuits and other disputes (patent, product liability, commercial, employment, Novum LVP class actions, DOJ CID), potentially resulting in significant liabilities, reduced sales, and diversion of management attention.
• Potential fines or exclusion from participation in federal or state healthcare programs if the company fails to comply with applicable laws and regulations.
• Inability to protect or enforce patents or other proprietary rights, or claims of infringement by others, which could materially damage competitiveness and business prospects.
• Additional tax expense or liabilities due to changes in tax laws (e.g., OECD Pillar Two, OBBBA), audits (IRS transfer pricing), or disagreements with tax authorities.
• Amended and Restated Bylaws could limit stockholders' ability to choose their preferred judicial forum for disputes with the company or its directors, officers, or employees.
• The recent decrease in the quarterly dividend to $0.01 per share, with no guarantee of future increases or continued payments, could adversely affect the market price of common stock.
• Common stock price has fluctuated significantly and may continue to do so due to market perceptions, product issues, financial results, management transitions, and macroeconomic conditions.

Future Outlook

The company expects to incur additional pre-tax cash costs of approximately $2 million through the completion of business optimization initiatives and anticipates further restructuring charges to mitigate dis-synergies from the Kidney Care business sale and optimize its operating model. Supply chain challenges and elevated inflation rates are expected to persist, and tariffs are projected to continue negatively affecting results. The timing for the release of the Novum LVP ship and installation hold remains uncertain, with no meaningful sales expected during this period. The company anticipates remaining in a U.S. valuation allowance position for at least the next twelve months, with potential material changes. It aims to achieve a net leverage target of approximately 3.0x by the end of 2026, and during this deleveraging period, intends to continue paying a reduced dividend, refrain from share repurchases, and be highly selective with acquisitions. Contributions of at least $10 million to the Puerto Rico pension plan and $5 million to foreign pension plans are expected in 2026, along with $15 million in net cash outflows for OPEB plans. The company also projects significant annual amortization expenses for definite-lived intangible assets through 2030 and expects to recognize a substantial portion of its remaining performance obligations as revenue over the next several years.

Management Comments

• Our global footprint and the critical nature of our products and services play a key role in expanding access to healthcare in emerging and developed countries.
• We have continued to execute on our disciplined capital allocation framework, which is designed to optimize stockholder value creation in a manner and timing consistent with our previously stated commitment to achieve our net leverage targets.
• We are committed to retaining our investment grade rating, including taking actions toward achieving a net leverage target of approximately 3.0x by the end of 2026 through ongoing debt repayment and financing activities.
• During this deleveraging period, we currently intend to continue paying a dividend (which we reduced in November 2025), not make any share repurchases and be highly selective with respect to any potential acquisitions.
• Our employees set the foundation for our ability to achieve our strategic objectives. They contribute to our success and are instrumental in driving operational execution and our ability to deliver on our stated goals and commitments, advance innovation and maintain a strong quality and compliance program across our organization.
• We believe our tax positions comply with applicable tax law and we intend to defend our positions.

Industry Context

StockSavvy.ai notes that Baxter's strategic divestitures (Kidney Care, BPS) and focus on a new operating model align with a broader industry trend of portfolio optimization and operational streamlining among large healthcare conglomerates. The challenges faced with supply chain disruptions, inflation, and increased competition are common across the medical products and pharmaceutical sectors, highlighting the ongoing pressures on margins and the need for continuous innovation and cost management. The increased regulatory scrutiny on product quality (e.g., Novum LVP recalls) and cybersecurity also reflects a tightening global regulatory environment impacting all industry players.

Comparison to Industry Standards

• The reported net loss and significant impairment charges, particularly in the Healthcare Systems & Technologies segment, contrast with the generally robust performance seen in certain specialized medical technology and pharmaceutical sub-sectors.
• The challenges in the IV solutions business due to 'fluid conservation practices embedded with clinical practice changes' suggest a market shift that other companies in similar product categories might also be experiencing or adapting to.
• The FDA's Class I recall classification for the Novum LVP is a serious regulatory event that can significantly impact market perception and sales, similar to high-profile recalls experienced by other medical device manufacturers.

Management Changes

Corporate Governance

Legal Proceedings

• Novum IQ Large Volume Pump (Novum LVP): Voluntary corrections initiated in April and July 2025 due to under-infusion and set misloading issues, classified as Class I recalls by the FDA. A temporary ship and installation hold was implemented in the U.S. and Canada in July 2025. Class action complaints were filed in October and December 2025 alleging violations of the Securities Exchange Act of 1934 and Rule 10b-5 related to allegedly false and misleading statements about Novum LVP. Two derivative complaints were filed in November 2025 alleging breaches of fiduciary duties and federal law in connection with public statements about Novum LVP, which were consolidated in January 2026. Stockholder requests for inspections of books and records have also been received.
• Environmental Matters: The company is involved as a potentially responsible party (PRP) for environmental clean-up costs at six Superfund sites and has an agreement in principle to resolve liability at a seventh. Ongoing environmental remediations are associated with historic operations at certain facilities, with reserves of $29 million as of December 31, 2025. Lawsuits filed since December 2023 in Cook County, Illinois, allege injuries from ethylene oxide used at the Round Lake, Illinois, facility, with an agreement in principle to resolve the remaining filed cases for an amount not material to Baxter.
• Hillrom Acquisition Related: The DOJ issued a Civil Investigative Demand (CID) in October 2022 and a subpoena in October 2024 to Hillrom, requesting documents and information related to compliance with the False Claims Act and Anti-Kickback Statute, particularly concerning Hillrom's respiratory health business. Baxter is cooperating. Linet Americas, Inc. filed an antitrust lawsuit in December 2021 against Hill-Rom Holdings, Inc. et al. alleging anti-competitive conduct in hospital bed markets, with fact discovery ongoing. A putative class action filed by Reading Hospital in June 2024 alleging antitrust violations was dismissed with prejudice in September 2025, but Reading Hospital filed a Notice of Appeal in October 2025.
• DOJ Civil Investigative Demand (CID) on IV Flexible Containers: Received a CID from the DOJ in December 2025 requesting documents and information related to the production of Baxter's IV flexible containers and compliance with the False Claims Act. The company is cooperating fully.

Related Party Transactions

• The company engages in intra-company transactions for inventory, services, licenses, and funding, which are subject to scrutiny by tax authorities regarding transfer pricing.
• Upon the sale of the Kidney Care business, Baxter and Vantive Health LLC (the divested entity) entered into a Manufacturing and Supply Agreement (Kidney Care MSA) and a Transition Services Agreement (Kidney Care TSA), under which they provide each other with certain products, components, and transitional services.

Stakeholder Impact

• Shareholders: Experience negative impact from net losses, significant impairment charges, reduced dividend, and ongoing litigation, but may benefit from strategic portfolio optimization and debt reduction efforts.
• Employees: Affected by management transitions and restructuring initiatives, which include employee termination costs. The company emphasizes competitive pay, benefits, health, safety, recruitment, and development programs.
• Customers: Face potential disruptions from product recalls (Novum LVP) and supply chain issues. Demand for IV solutions is impacted by fluid conservation practices. Pricing pressures from GPOs and IDNs continue.
• Suppliers: Subject to supply chain disruptions, increased costs for raw materials and components, and the need to comply with quality standards. Reliance on single-source suppliers poses risks.
• Creditors: Impacted by the company's significant indebtedness and debt repayment strategies. The commitment to retaining an investment grade rating is crucial, but potential for further credit rating downgrades exists.

Next Steps

• Continue to implement business optimization programs and cost savings initiatives, including those to mitigate dis-synergies from the Kidney Care business sale.
• Further optimize the business and manufacturing footprint.
• Develop additional corrections for Novum LVP recalls, some of which may require regulatory clearance or approval.
• Work towards achieving a net leverage target of approximately 3.0x by the end of 2026 through ongoing debt repayment and financing activities.
• Continue paying a dividend (though reduced), not make share repurchases, and be highly selective with acquisitions during the deleveraging period.
• Make contributions of at least $10 million to the Puerto Rico pension plan and $5 million to foreign pension plans in 2026.
• Manage net cash outflows relating to OPEB plans of $15 million in 2026.
• Monitor regulatory guidance and interpretations for the One Big Beautiful Bill Act (OBBBA) and OECD Pillar Two legislation.
• Respond to IRS inquiries regarding transfer pricing matters for 2019 and 2020 tax years.
• Address ongoing class action and derivative lawsuits related to Novum LVP.
• Cooperate with the DOJ in responding to the Civil Investigative Demand (CID) regarding IV flexible containers.
• Reading Hospital's appeal of the dismissal of its class action lawsuit is underway.
• The Annual Meeting of Stockholders is expected to be held on May 5, 2026.

Key Dates

Recommendation

The company reported a substantial net loss, significant goodwill and intangible asset impairments, and a critical Class I recall for a key product (Novum LVP) leading to a sales hold. The dividend reduction further signals financial strain. While strategic divestitures aim to improve the long-term financial position, the immediate operational challenges, increased tax liabilities, and ongoing litigation create considerable near-term uncertainty and downside risk for investors.

Keywords

Healthcare, Medical Technology, Pharmaceuticals, Medical Devices, Infusion Systems, Patient Monitoring, Surgical Equipment, Deferred Compensation, SEC Filing, 10-K, Financial Results, Divestitures, Acquisitions, Risk Management, Corporate Governance, Supply Chain, Regulatory Compliance, Product Recalls, Goodwill Impairment, Tax Liabilities, Debt Repayment, Shareholder Value, Baxter International Inc., Novum LVP, Hillrom